Zura Bio Ltd
ZURA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001855644
No open-market purchases or sales by Zura Bio Ltd insiders were filed in the last 90 days; 95 institutions reported holding it in 13F filings for Q2 2026, worth $428.9M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 10, 2026
- $135.3M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +2 vs. previous quarter
- 95
- 13F valueReported value at the end of Q2 2026
- $428.9M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- –
- No comparable prior period
- Net income, FY2025
- -$68.7M
- No comparable prior period
- Free cash flow, FY2025
- -$64.9M
- No comparable prior period
- Revenue, Q3 FY2026
- –
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 8.47M
- Shares sold short
- Change
- +1.45M
- +20.7% vs. previous
- Days to cover
- 1.79
- At average daily volume
Superinvestors holding ZURA, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding ZURA at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Zura Bio Ltd insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 2, 2026 (view filing)5:55 PM ET | Feb 26 | 4 days | Blavatnik Len and 3 others10% Owner | PPurchaseClass A Ordinary Shares | +2.00M | $6.25 | +$12.5M | +43.9%6.55M after | |
| Nov 27, 2024 (view filing) | Nov 25 | 2 days | Thiara ParvinderDirector | SSaleClass A Ordinary Shares | −1.00M | $2.73 | −$2.73M | −100.0%0 after | |
| Sep 13, 2024 (view filing) | Sep 11 | 2 days | Thiara ParvinderDirector | SSaleClass A Ordinary Shares | −3.80M | $2.70 | −$10.3M | −79.1%1.00M after | |
| Sep 6, 2024 (view filing) | Sep 4 | 2 days | Sidhu SomeitDirector | SSaleClass A ordinary shares | −51.7K | $3.87 | −$200.2K | −2.4%2.09M after | |
| May 23, 2024 (view filing) | May 17 | 6 daysLate | Ploos van Amstel ArnoutDirector | PPurchaseClass A ordinary shares | +80.0K | $6.20 | +$496.0K | +400.0%100.0K after | |
| Dec 14, 2023 (view filing) | Dec 12 | 2 days | Thiara ParvinderDirector, 10% Owner | SSaleClass A Ordinary Shares | −2.00M | $4.00 | −$8.00M | −29.4%4.80M after | |
| Dec 13, 2023 (view filing) | Dec 11 | 2 days | Sidhu SomeitChief Executive Officer | PPurchaseClass A Ordinary Shares | +1.75M | – | – | –1.75M after | Derivative |
| Jun 22, 2023 (view filing)5:21 PM ET | Jun 15 | 7 daysLate | Athanor Capital, LP10% Owner | SSaleClass A Ordinary Shares | −1.19M | $0.25 | −$298.5K | –0 after | Derivative |
| Jun 5, 2023 (view filing) | Jun 5 | Same day | Munshi AmitDirector | PPurchaseClass A Ordinary Shares | +117.6K | $4.25 | +$500.0K | +23.5%617.6K after |
Top 10 13F holders, Q2 2026
See all 95 holdersThe largest institutional positions in Zura Bio Ltd at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Suvretta Capital Management, LLC | 9,443,001 | $55.7M | 1.17% | +376,000+4.1% | Added |
| VR Adviser, LLC | 6,434,990 | $38.0M | 1.15% | 00.0% | Unchanged |
| MPM Oncology Impact Management LP | 4,472,843 | $26.4M | 1.61% | +4,472,843 | New |
| Great Point Partners LLC | 4,215,930 | $24.9M | 5.86% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 4,354,715 | $24.5M | 0.00% | −104,136−2.3% | Reduced |
| Braidwell LP | 3,980,295 | $23.5M | 0.87% | −8,694−0.2% | Reduced |
| Siren, L.L.C. | 3,734,866 | $22.0M | 0.45% | 00.0% | Unchanged |
| BlackRock, Inc. | 3,614,695 | $21.3M | 0.00% | +3,157,336+690.3% | Added |
| Commodore Capital LP | 3,250,000 | $19.2M | 1.14% | 00.0% | Unchanged |
| Adage Capital Partners GP, L.L.C. | 2,750,000 | $16.2M | 0.02% | 00.0% | Unchanged |
Holders of 5% or more of ZURA
See all 4 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Zura Bio Ltd.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| AI Biotechnology LLC | 13D/A | 18.20%19.7M shares | −1.70 ppfrom 19.90% | May 28, 20252 filings | Mar 2, 2026 | SEC |
| Athanor Capital | 13D | 15.70%11.6M shares | 0.00 ppfrom 15.70% | Jan 2, 20262 filings | Jan 27, 2026 | SEC |
| Venrock Healthcare Capital Partners III, L.P. | 13G/A | 9.90%9.82M shares | 0.00 ppfrom 9.90% | May 2, 20245 filings | May 15, 2026 | SEC |
| Suvretta Capital Management, LLC | 13G/A | 9.90%9.52M shares | +1.30 ppfrom 8.60% | Jun 15, 20234 filings | May 12, 2026 | SEC |